Please use this identifier to cite or link to this item:
|Title:||The impact of hyperfiltration on the diabetic kidney.|
|Authors:||Premaratne, Erosha;Verma, S;Ekinci, Elif I;Theverkalam, G;Jerums, George;MacIsaac, Richard J|
|Affiliation:||Endocrine Centre & Department of Medicine, Austin Health & University of Melbourne, Victoria, Australia.|
Endocrine Centre & Department of Medicine, Austin Health & University of Melbourne, Victoria, Australia; Menzies Institute of Health Research, Darwin, Northern Territory, Australia.
Departments of Endocrinology & Diabetes and Medicine, St Vincent's Hospital Melbourne & University of Melbourne, Victoria, Australia.
Departments of Endocrinology & Diabetes and Medicine, St Vincent's Hospital Melbourne & University of Melbourne, Victoria, Australia. Electronic address: email@example.com.
|Citation:||Diabetes & Metabolism 2014; 41(1): 5-17|
|Abstract:||More than two decades ago, hyperfiltration (HF) in diabetes was postulated to be a maladaptive response observed early in the course of diabetic kidney disease (DKD), which may eventually predispose to irreversible damage to nephrons and development of progressive renal disease. Despite this, the potential mechanisms leading to renal HF in diabetes are not fully understood, although several hypotheses have been proposed, including alterations in glomerular haemodynamic function and tubulo-glomerular feedback. Furthermore, the role of HF as a causative factor in renal disease progression is still unclear and warrants further prospective longer-term studies. Although HF has been entrenched as the first stage in the classic albuminuric pathway to end-stage renal disease in DKD, and HF has been shown to predict the progression of albuminuria in many, but not all studies, the concept that HF predisposes to the development of chronic kidney disease (CKD) stage 3, that is, glomerular filtration rate (GFR) decline to<60mL/min/1.73m(2), remains to be proved. Further long-term studies of GFR gradients therefore are required to establish whether HF ultimately leads to decreased kidney function, after adjustment for glycaemic control and other confounders. Whether reversal of HF with therapeutic agents is protective against reducing the risk of development of albuminuria and renal impairment is also worth investigating in prospective randomized trials.|
|Internal ID Number:||25457474|
|Subjects:||Diabetic kidney disease|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.